U.S. Markets closed

OncoGenex announces data from Phaes 2 study of OGX-427

OncoGenex announced data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer patients. Preliminary results show a higher number of patients taking OGX-427 plus prednisone without disease progression at 12 weeks and with declines in prostate-specific antigen, compared with those taking prednisone alone.